Study of D-2570 in Subjects With Non-Segmental Vitiligo (D2570-206)
A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
調査の概要
詳細な説明
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of D-2570 in subjects with non-segmental vitiligo. The study consists of three periods: a screening period (up to 4 weeks), a 24-week double-blind treatment period, and a 24-week extension treatment period, followed by a 4-week safety follow-up period.
During the screening period, written informed consent will be obtained from each subject, and eligibility will be assessed based on predefined inclusion and exclusion criteria. Subjects who meet all eligibility criteria will be stratified according to baseline vitiligo severity (T-VASI <15 or ≥15) and disease activity (active or stable), then randomized in a 1:1:1:1 ratio to one of four treatment groups: D-2570 Group A, D-2570 Group B, D-2570 Group C, or placebo.
During the 24-week double-blind treatment period, subjects will receive once-daily oral study medication. Subjects in Groups A and B will continue the same dose in the subsequent 24-week extension period. Subjects in Group C and the placebo group will be re-randomized in a 1:1 ratio to either Group A or Group B for the extension period, maintaining the blind.
All subjects will attend study visits at protocol-specified time points, including assessments of efficacy (including T-VASI), safety (including adverse events, clinical laboratory tests, vital signs, and physical examinations), and pharmacokinetic evaluations via blood sampling. The study will conclude with an end-of-study (EOS) visit at Week 52, 4 weeks after the last dose of study medication, to collect final safety data. All subjects, investigators, and study site personnel will remain blinded to treatment assignments throughout the study.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前：shilin Sha
- 電話番号：15601826678
- メール：shilin.sha@inventisbio.com
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、201203
- 募集
- Huashan Hospital, Fudan University
-
コンタクト：
- shilin Sha
- 電話番号：15601826678
- メール：shilin.sha@inventisbio.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Voluntarily signs informed consent and complies with study procedures.
- Age 18-65 years, male or female.
- Clinical diagnosis of non-segmental vitiligo at screening.
- F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.
- Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion Criteria:
- - Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment.
- Over 33% facial or total vitiligo lesions with leukotrichia.
- Pregnant or breastfeeding females.
- Active, latent or inadequately treated tuberculosis infection.
- Positive HIV, active HBV/HCV infection, or untreated syphilis.
- Current or history of severe herpes infection.
- Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.
- Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.
- Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders.
- Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months.
- Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).
- Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.
- Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.
- History of severe drug hypersensitivity or drug-related toxicity.
- Any condition that may impair protocol compliance or study participation per investigator judgment.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：D-2570 Dose 1 (experimental arm 1)
Subjects in this arm will receive oral D-2570 Dose 1 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 1 in the subsequent 24-week extension period.
|
Oral D-2570 Dose 1 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period
|
|
実験的：D-2570 Dose 2 (experimental arm 2)
Subjects in this arm will receive oral D-2570 Dose 2 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 2 in the subsequent 24-week extension period
|
Oral D-2570 Dose 2 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period.
|
|
実験的：D-2570 Dose 3 (experimental arm 3)
Subjects in this arm will receive oral D-2570 Dose 3 once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral D-2570 Dose 3 administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
|
プラセボコンパレーター：placebo
Subjects in this arm will receive matching placebo once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral placebo administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI)
時間枠：week24
|
Change rate of facial vitiligo area, measured by F-VASI score, relative to baseline
|
week24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change and percentage change from baseline in F-VASI
時間枠：Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in facial vitiligo area, measured by F-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving F-VASI50/75/90
時間枠：Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in F-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Change and percentage change from baseline in T-VASI
時間枠：Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in total vitiligo area, measured by T-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving T-VASI50/75/90
時間枠：Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in T-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects with F-PhGVA score 0 or 1
時間枠：Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with F-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with T-PhGVA score 0 or 1
時間枠：Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with T-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with VNS score 4 or 5
時間枠：Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with VNS score of 4 (hardly noticeable) or 5 (not noticeable).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in DLQI score
時間枠：Weeks 8, 16, 24, 32, 40, and 48
|
Change in Dermatology Quality of Life Index (DLQI) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in VitiQoL score
時間枠：Weeks 8, 16, 24, 32, 40, and 48
|
Change in Vitiligo-Specific Quality of Life (VitiQoL) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Plasma concentrations of D-2570
時間枠：Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
|
|
Safety of D-2570（AEs）
時間枠：Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- D2570-206
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。